Prasheen Agarwal

2.4k total citations · 2 hit papers
29 papers, 1.7k citations indexed

About

Prasheen Agarwal is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Prasheen Agarwal has authored 29 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Rheumatology, 14 papers in Immunology and 12 papers in Hematology. Recurrent topics in Prasheen Agarwal's work include Psoriasis: Treatment and Pathogenesis (13 papers), Spondyloarthritis Studies and Treatments (11 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Prasheen Agarwal is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (13 papers), Spondyloarthritis Studies and Treatments (11 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Prasheen Agarwal collaborates with scholars based in United States, United Kingdom and Canada. Prasheen Agarwal's co-authors include Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, Yanli Zhuang, Ashwin Gollerkeri, Jane F. Apperley, Andreas Hochhaus, Susan Branford and François Guilhot and has published in prestigious journals such as The Lancet, Blood and Annals of the Rheumatic Diseases.

In The Last Decade

Prasheen Agarwal

27 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

2020 242 citations Philip J. Mease, Proton Rahman et al. The Lancet profile →
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

2020 233 citations Atul Deodhar, Philip Helliwell et al. The Lancet profile →

Peers

Countries citing papers authored by Prasheen Agarwal

Since Specialization

Citations

This map shows the geographic impact of Prasheen Agarwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prasheen Agarwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prasheen Agarwal more than expected).

Fields of papers citing papers by Prasheen Agarwal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prasheen Agarwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prasheen Agarwal. The network helps show where Prasheen Agarwal may publish in the future.

Co-authorship network of co-authors of Prasheen Agarwal

This figure shows the co-authorship network connecting the top 25 collaborators of Prasheen Agarwal. A scholar is included among the top collaborators of Prasheen Agarwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prasheen Agarwal. Prasheen Agarwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of elobixibat in patients with chronic constipation—A randomized, multicenter, double-blind, placebo-controlled, parallel-group study from India 2025 ·Indian Journal of Gastroenterology ·Prasheen Agarwal, (unknown), (unknown), B. Sahaya Infant Lasalle, (unknown), (unknown), Vinay Kumar, (unknown), (unknown), (unknown), Omesh Goyal, Ashima Bhatia	2
2	Efficacy and Safety of Tegoprazan in Patients with Erosive Gastroesophageal Reflux Disease- A Multicountry, Prospective, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study 2025 ·Prasheen Agarwal, (unknown), (unknown), (unknown), (unknown), Sachin Wani, (unknown), Rakesh Patel, (unknown), Geun Seog Song	0
3	Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn 2024 ·American Journal of Perinatology ·(unknown), (unknown), Eleonor Tiblad, Enrico Lopriore, Dick Oepkes, Prasheen Agarwal, (unknown), Jocelyn H. Leu, (unknown), Robert M. Nelson, (unknown), (unknown), May Lee Tjoa, (unknown), (unknown), (unknown), Kenneth J. Moise	7
4	The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial 2022 ·Advances in Therapy ·Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, Steven L. Peterson, Prasheen Agarwal, (unknown), Alexa P. Kollmeier, Elizabeth C. Hsia, Natalie J. Shiff, Bei Zhou, Chenglong Han, M. Shawi, William Tillett, Philip J. Mease	3
5	The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial 2022 ·Advances in Therapy ·Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, (unknown), Steven L. Peterson, Prasheen Agarwal, Alexa P. Kollmeier, Elizabeth C. Hsia, Chenglong Han, Natalie J. Shiff, M. Shawi, William Tillett, Philip J. Mease	5
6	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced 2021 ·RMD Open ·Christopher T. Ritchlin, Philip Helliwell, Wolf‐Henning Boehncke, Enrique R. Soriano, Elizabeth C. Hsia, Alexa P. Kollmeier, Soumya D. Chakravarty, (unknown), Ramanand A. Subramanian, Xie L. Xu, Qing Zuraw, Shihong Sheng, (unknown), Prasheen Agarwal, Bei Zhou, Yanli Zhuang, M. Shawi, Chetan S. Karyekar, Atul Deodhar	50
7	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies 2021 ·The Lancet Rheumatology ·Philip J. Mease, Philip Helliwell, Dafna D. Gladman, Denis Poddubnyy, Xenofon Baraliakos, Soumya D. Chakravarty, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Kristen Sweet, M. Shawi, Chetan S. Karyekar, Atul Deodhar, Désirée van der Heijde	61
8	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis 2021 ·The Journal of Rheumatology ·Proton Rahman, Christopher T. Ritchlin, Philip Helliwell, Wolf‐Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Shelly Kafka, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, M. Shawi, Shihong Sheng, Prasheen Agarwal, Bei Zhou, (unknown), Yanli Zhuang, Iain B. McInnes	19
9	Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis 2020 ·Arthritis & Rheumatology ·Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, Elizabeth C. Hsia, Alexa P. Kollmeier, Soumya D. Chakravarty, Xie L. Xu, Ramanand A. Subramanian, Prasheen Agarwal, Shihong Sheng, (unknown), Bei Zhou, Yanli Zhuang, Désirée van der Heijde, Philip J. Mease	56
10	Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial breakdown → 2020 ·The Lancet ·Atul Deodhar, Philip Helliwell, Wolf‐Henning Boehncke, Alexa P. Kollmeier, Elizabeth C. Hsia, Ramanand A. Subramanian, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, Christopher T. Ritchlin	233
11	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial breakdown → 2020 ·The Lancet ·Philip J. Mease, Proton Rahman, Alice B. Gottlieb, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, B. Zhou, Yanli Zhuang, Désirée van der Heijde, Iain B. McInnes	242
12	FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS 2020 ·Annals of the Rheumatic Diseases ·Proton Rahman, Christopher T. Ritchlin, Philip Helliwell, Wolf‐Henning Boehncke, (unknown), Alice B. Gottlieb, Shelly Kafka, Alexa P. Kollmeier, Elizabeth C. Hsia, X. L. Xu, M. Shawi, (unknown), Prasheen Agarwal, B. Zhou, Padmakumar Ramachandran, Iain B. McInnes	1
13	15281 Effects of guselkumab on articular components of American College of Rheumatology score and skin responses in patients with active psoriatic arthritis: Results from the phase 3 DISCOVER-2 study 2020 ·Journal of the American Academy of Dermatology ·Alice B. Gottlieb, Philip J. Mease, Joseph F. Merola, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Prasheen Agarwal, Désirée van der Heijde, Iain B. McInnes, Wolf‐Henning Boehncke	2
14	SAT0402 EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBUNIT OF INTERLEUKIN-23, THROUGH WEEK 52 OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS 2020 ·Annals of the Rheumatic Diseases ·Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, Elizabeth C. Hsia, Alexa P. Kollmeier, X. L. Xu, Ramanand A. Subramanian, Prasheen Agarwal, (unknown), (unknown), Bei Zhou, D. van der Heijde, Philip J. Mease	2
15	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study 2017 ·The Lancet ·Daniel Aletaha, Clifton O. Bingham, Yoshiya Tanaka, Prasheen Agarwal, Regina Kurrasch, Paul P. Tak, (unknown)	82
16	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab 2015 ·European Respiratory Journal ·Ganesh Raghu, Fernando J. Martínez, Kevin K. Brown, Ulrich Costabel, Vincent Cottin, Athol U. Wells, Lisa Lancaster, Kevin F. Gibson, Tarik Haddad, Prasheen Agarwal, M. Mack, B. Dasgupta, Ivo Nnane, Susan Flavin, Elliot S. Barnathan	101
17	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis 2014 ·European Respiratory Journal ·Marc A. Judson, Robert P. Baughman, Ulrich Costabel, Marjolein Drent, Kevin F. Gibson, Ganesh Raghu, Hidenobu Shigemitsu, Joseph B. Barney, Daniel A. Culver, Nabeel Hamzeh, Marlies Wijsenbeek, Carlo Albera, Isham Huizar, Prasheen Agarwal, Carrie Brodmerkel, Rosemary Watt, Elliot S. Barnathan	153
18	Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease 2012 ·Respiratory Medicine ·Stephen I. Rennard, Susan Flavin, Prasheen Agarwal, Kim Hung Lo, Elliot S. Barnathan	23
19	Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i). 2006 ·Blood ·Giovanni Martinelli, Andreas Hochhaus, Steven Coutré, Jane F. Apperley, Neha Shah, Ashwin Gollerkeri, Prasheen Agarwal, Oliver G. Ottmann	16
20	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis 2006 ·Blood ·Jörge E. Cortes, Philippe Rousselot, Dong‐Wook Kim, Ellen K. Ritchie, Nelson Hamerschlak, Steven Coutré, Andreas Hochhaus, François Guilhot, Giuseppe Saglio, Jane F. Apperley, Oliver G. Ottmann, Neil P. Shah, Philipp Erben, Susan Branford, Prasheen Agarwal, Ashwin Gollerkeri, Michele Baccarani	301

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact